JP2024539946A5 - - Google Patents

Info

Publication number
JP2024539946A5
JP2024539946A5 JP2024524568A JP2024524568A JP2024539946A5 JP 2024539946 A5 JP2024539946 A5 JP 2024539946A5 JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024539946 A5 JP2024539946 A5 JP 2024539946A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
stereoisomer
acceptable salt
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/128293 external-priority patent/WO2023072257A1/en
Publication of JP2024539946A publication Critical patent/JP2024539946A/ja
Publication of JP2024539946A5 publication Critical patent/JP2024539946A5/ja
Pending legal-status Critical Current

Links

JP2024524568A 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法 Pending JP2024539946A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/127023 2021-10-28
CN2021127023 2021-10-28
CN2022112270 2022-08-12
CNPCT/CN2022/112270 2022-08-12
PCT/CN2022/128293 WO2023072257A1 (en) 2021-10-28 2022-10-28 Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024539946A JP2024539946A (ja) 2024-10-31
JP2024539946A5 true JP2024539946A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=86159087

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024524568A Pending JP2024539946A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法
JP2024524567A Pending JP2024541910A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024524567A Pending JP2024541910A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法

Country Status (11)

Country Link
US (6) US20260015349A1 (cg-RX-API-DMAC7.html)
EP (2) EP4422623A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024539946A (cg-RX-API-DMAC7.html)
KR (2) KR20240095274A (cg-RX-API-DMAC7.html)
CN (2) CN118591533A (cg-RX-API-DMAC7.html)
AR (3) AR127488A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022378858A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235718A1 (cg-RX-API-DMAC7.html)
IL (1) IL312220A (cg-RX-API-DMAC7.html)
TW (3) TW202332677A (cg-RX-API-DMAC7.html)
WO (3) WO2023072240A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
GB202301059D0 (en) 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors
JP2026516849A (ja) * 2023-04-28 2026-05-26 インシリコ メディスン アイピー リミテッド プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤、その組合せ及び使用
WO2024222881A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
CN121057737A (zh) * 2023-04-28 2025-12-02 英矽智能科技知识产权有限公司 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂结晶及其用途
CN117603230B (zh) * 2023-12-15 2025-03-21 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的三并环类化合物
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物
CN117756822B (zh) * 2023-12-20 2025-04-18 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶氨基类化合物
CN117736227B (zh) * 2023-12-20 2025-01-21 英矽智能科技(上海)有限公司 抑制jak和phd的一类化合物
CN117924326B (zh) * 2024-01-23 2025-01-21 英矽智能科技(上海)有限公司 一类抑制jak和phd的三并环类化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20040176366A1 (en) * 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0505621D0 (en) * 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US20110028507A1 (en) * 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
EP2240178A4 (en) * 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
WO2011106226A2 (en) 2010-02-23 2011-09-01 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2013134660A1 (en) * 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146491B (zh) * 2015-03-27 2017-12-12 沈阳三生制药有限责任公司 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途
CN106146490B (zh) 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN108341777A (zh) 2017-01-23 2018-07-31 四川科伦博泰生物医药股份有限公司 异喹啉酮类化合物及其应用
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CN109575016B (zh) * 2017-09-28 2022-01-04 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
CN110878096A (zh) 2018-09-05 2020-03-13 石药集团中奇制药技术(石家庄)有限公司 一种1,7-萘啶类衍生物及其制备方法和用途
CN112979541B (zh) 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
MX2022010011A (es) * 2020-02-12 2022-10-18 Amgen Inc Inhibidores de prmt5 novedosos.
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2024541910A5 (cg-RX-API-DMAC7.html)
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2024100974A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2025507292A5 (cg-RX-API-DMAC7.html)
JP2009524691A5 (cg-RX-API-DMAC7.html)
JP2021522280A5 (cg-RX-API-DMAC7.html)
JP2025502943A5 (cg-RX-API-DMAC7.html)
JP2024542969A5 (cg-RX-API-DMAC7.html)
JP2025508971A5 (cg-RX-API-DMAC7.html)
JP2025503953A5 (cg-RX-API-DMAC7.html)
JP2006516143A5 (cg-RX-API-DMAC7.html)
JP2025513882A5 (cg-RX-API-DMAC7.html)
JP2021523200A5 (cg-RX-API-DMAC7.html)
JP2025505994A5 (cg-RX-API-DMAC7.html)
JP2025507915A5 (cg-RX-API-DMAC7.html)
JP2005500311A5 (cg-RX-API-DMAC7.html)
JP2016515096A5 (cg-RX-API-DMAC7.html)
JP2013516518A5 (cg-RX-API-DMAC7.html)
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP2007512359A5 (cg-RX-API-DMAC7.html)
JP2017502006A5 (cg-RX-API-DMAC7.html)
JP2024534420A5 (cg-RX-API-DMAC7.html)
JP2020535124A5 (cg-RX-API-DMAC7.html)